Log in or Sign up for Free to view tailored content for your specialty!
Gastrointestinal Cancer News
Tarextumab granted orphan drug designation for pancreatic, small cell lung cancers
The FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small cell lung cancer, the drug’s manufacturer announced today.
Confocal laser endomicroscopy improved detection of biliary cancer
When combined with tissue sampling, using probe-based confocal laser endomicroscopy during endoscopic retrograde cholangio-pancreatography diagnosed cholangiocarcinoma with greater accuracy and sensitivity compared with standard procedures, according to new research data.
Log in or Sign up for Free to view tailored content for your specialty!
Lanreotide shows promise in patients with pancreatic neuroendocrine tumors
Lanreotide demonstrated antitumor activity with a manageable safety profile in patients with pancreatic neuroendocrine tumors, according to a subgroup analysis of the CLARINET study presented at the Gastrointestinal Cancers Symposium.
CRC incidence increasing in young adults
The incidence of colorectal cancer is increasing among the young adult population while decreasing among adults in the screened population, according to new research data.
Pembrolizumab appears safe, effective in advanced gastric cancer
The novel agent pembrolizumab demonstrated promising antitumor activity and manageable toxicity in patients with advanced gastric cancer, according to study results presented at the Gastrointestinal Cancers Symposium.
Integrated health care may eliminate racial disparities in colon cancer survival
Providing fair, high-quality, evidence-based care can eliminate racial disparities in survival outcomes among patients with colon cancer, according to results of a retrospective study.
MM-398 improved outcomes in metastatic pancreatic cancer
The addition of the novel agent MM-398 to second-line 5-FU/leucovorin extended survival in patients with metastatic pancreatic cancer, according to an expanded analysis of the phase 3 NAPOLI-1 trial presented at the Gastrointestinal Cancer Symposium.
Temsirolimus, bevacizumab shows promise for pancreatic neuroendocrine tumors
Combination treatment with temsirolimus and bevacizumab demonstrated considerable activity and a reasonable safety profile in patients with progressive pancreatic neuroendocrine tumors, according to results of a phase 2 trial.
ATRX mutation possible biomarker for rare neuroendocrine tumors
A somatic mutation in the ATP-dependent helicase, or ATRX, gene — recently demonstrating potential as a molecular marker for aggressive brain tumors — could also serve as a biomarker for rare neuroendocrine tumors, according to research published in Nature Communications.
Molecular subtypes of CRC associated with differences in patient survival
Different molecular subtypes of colorectal cancer were found to be associated with significant differences in patient survival, according to new research data.
-
Headline News
Open-label placebo injection demonstrates ‘modest’ benefit in chronic back pain
October 23, 20242 min read -
Headline News
GLP-1, SGLT2 prescriptions for type 1 diabetes rising despite no regulatory approval
October 23, 20243 min read -
Headline News
CDC: 1 dead in multistate E. coli outbreak linked to McDonald’s Quarter Pounders
October 22, 20241 min read
-
Headline News
Open-label placebo injection demonstrates ‘modest’ benefit in chronic back pain
October 23, 20242 min read -
Headline News
GLP-1, SGLT2 prescriptions for type 1 diabetes rising despite no regulatory approval
October 23, 20243 min read -
Headline News
CDC: 1 dead in multistate E. coli outbreak linked to McDonald’s Quarter Pounders
October 22, 20241 min read